I get make heads or tails of the 2000 agreement which seems to hinge on duotheraputic uses.What's the deal here? Anybody know?
The best T will do is a blackbox label, BIIB will offer Elan its half of a worthless pie for royalties. Blackbox label means detailing will be expensise given their are 4 other MS drugs with no serious label restrictions.
I would consider that to be poor thinking if BIIB wasn't on the move. There is no way that T approved for mono trials can be good for BIIB for Avonex with shrivel to nothing.